drugset / Trial / NCT00525447
Study of SGN-40, Lenalidomide, and Dexamethasone in Patients With Multiple Myeloma
NaSingle-groupOpen-labelTreatment
Summary
This is a Phase I, open-label, multi-dose trial to define the MTD and tolerability of a regimen including lenalidomide, dexamethasone, and intravenous SGN-40 in patients with relapsed multiple myeloma.
Timeline
- Start
- 2007-08
- Primary completion
- 2010-01
- Completion
- 2010-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dexamethasone | Small molecule | 40 mg | — |
| Subject | Lenalidomide | Other / unclassified | 25 mg | — |
| Subject | dacetuzumab | Monoclonal antibody | 2 mg/kg | Intravenous |
| Subject | dacetuzumab | Monoclonal antibody | 4 mg/kg | Intravenous |
| Subject | dacetuzumab | Monoclonal antibody | 12 mg/kg | Intravenous |